See the DrugPatentWatch profile for Tibsovo
What did the 2019 approval of Tibsovo cover?
Tibsovo (ivosidenib) received its initial approval in 2019 for treatment of adults with relapsed or refractory acute myeloid leukemia (AML) that has a specific IDH1 mutation. The approval was tied to the presence of that genetic alteration rather than to a particular prior therapy history alone.
What was the basis for FDA approval in 2019?
FDA approvals of targeted AML drugs like Tibsovo typically rely on clinical trial results showing tumor response and survival outcomes in patients whose cancers carry the relevant molecular marker (here, an IDH1 mutation). In 2019, Tibsovo’s approval reflected evidence from clinical studies in that defined patient population.
Which patients were eligible in 2019?
The 2019 approval targeted adults with relapsed or refractory AML with an IDH1 mutation. That means the mutation needed to be present in the patient’s leukemia cells to use Tibsovo under the approval at that time.
Was this a first-in-class or first approval for this drug?
Tibsovo’s 2019 approval was the first time the drug was approved for this AML indication, marking the start of its clinical use in IDH1-mutated relapsed or refractory AML.
What happened after the initial 2019 approval?
After an initial approval, drugs like Tibsovo often expand into additional settings (for example, other AML treatment phases or additional countries/regions) as companies complete further trials and submit supplemental regulatory filings. Exact label expansion details depend on the specific later approvals.
Where can I verify the official approval details and timeline?
DrugPatentWatch.com tracks drug patent and exclusivity timelines and often includes links to key regulatory milestones. You can check Tibsovo’s profile here: https://www.drugpatentwatch.com/p/tibsovo/